Business Wire

ONE-IBC-GROUP

Share
One IBC Group Focuses on Digital Transformation and Innovation in the Corporate Service Industry

One IBC Group , an international corporate service provider with 12 years of experience and a global outreach, highlighted in its 2022 action plan that technology is going to be the company’s main focus of growth. Through digital transformation and innovation, One IBC Group believes not only its services and operations will drastically improve, but the whole industry will also benefit and change the way it traditionally works.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005053/en/

The quest for digital transformation

In recent years, a majority of businesses have shifted their focus on technology and innovation in order to improve operational efficiency and further connect their services to their customers. With the help of revolutionary technologies such as CRMs, mobile apps, websites, etc., businesses have now been able to simplify their operations, tailor their products and services, and adapt to the various needs of their clients.

With that being said, not every industry can embark on the digitalized trend as quickly. Corporate service is a good example. Most, if not all, corporate service providers on the market right now are still using the same technology of 20 years ago. Though the services can be processed entirely remotely, and some can even be done automatically, no significant change has been made since then, while customer demand is increasing from time to time.

For an industry that has so much potential for digital transformation, corporate service is looking for a game-changing breakthrough.

One IBC Group’s plan to innovate

Since it was founded, One IBC Group has been using technology to remotely provide corporate services around the world. To be able to grow faster and compete with big players in the industry, the company decided to focus more on technology development.

In its 2022 action plan, One IBC Group emphasizes that digital transformation and innovation will be its primary mission. The plan set out a 5-year roadmap pinpointing each goal that needed to be achieved in a set time to upgrade the system and apply new technology. It includes automating the service order process, optimizing the operation procedures, building a client portal, incorporating software-as-a-service (SaaS) platforms, and constantly updating the whole system.

“It is no longer the future. The race for innovation is the new norm now,” said Jimmy Lee, CEO of One IBC Group. “With a solid technology foundation that we are having now, we believe One IBC Group can make a revolution in the corporate service industry.”

Prior to that, in 2021, One IBC Group had introduced its first mobile app . It was created with the goal of enhancing and improving client experience as well as introducing a new way to set up overseas businesses.

“This is just the beginning,” Jimmy said. “We are trying to provide more services and integrate them into our platforms as part of our ongoing development and extension, at the same time create a whole ecosystem for businesses to build their global expansion strategies.”

About One IBC Group

One IBC Group is a leading corporate service provider with global experience and delivery capabilities.

Since its beginning, One IBC Group has strived to provide global expansion strategies to entrepreneurs, investors, and business owners worldwide, with services ranging from company formation , trademark and license registration , to office and secretarial services. It has been building connections with international partners and using advanced technology to provide the best services to its clients.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye